Labcorp stock (US50540R4092): Expands Epic Integration for Diagnostic Testing

Labcorp announced an expanded collaboration with Epic on May 12, 2026, making its full test menu available through Epic's Aura platform to streamline lab ordering for hospitals nationwide.

Labcorp announced an expanded collaboration with Epic Systems Corporation on May 12, 2026, to integrate the company's full diagnostic test menu into Epic's Aura platform, a unified system for ordering and receiving lab results. The integration aims to streamline lab ordering workflows, reduce IT complexity, and expand access to advanced genetic and specialty diagnostics for hospitals and health systems using Epic nationwide, according to Labcorp's announcement as of May 12, 2026.

As of: May 12, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Laboratory Corporation of America Holdings
• Sector/industry: Diagnostic testing and drug development services
• Headquarters/country: Burlington, North Carolina, United States
• Core markets: Clinical laboratory services, drug development, genetic testing
• Key revenue drivers: Laboratory testing services, specialty diagnostics, pharmaceutical development support
• Home exchange/listing venue: NYSE (LH)
• Trading currency: USD

Labcorp: Core Business Model

Labcorp operates as a global life sciences company providing comprehensive clinical laboratory and drug development services. The company maintains a broad network of laboratories, patient service centers, and specialty testing sites across the United States and internationally. Labcorp serves healthcare providers, hospitals, pharmaceutical companies, researchers, and patients by delivering diagnostic information and testing solutions that support clinical decision-making and drug development processes.

Main Revenue and Product Drivers for Labcorp

Labcorp's revenue streams include routine clinical laboratory testing, specialty diagnostics including genetic testing through its Invitae portfolio, and drug development services for pharmaceutical companies. The company's integration with electronic health record systems like Epic's Aura platform represents a strategic expansion of distribution channels, allowing health systems to access Labcorp's test menu directly within existing clinical workflows. This integration reduces friction in test ordering and results delivery, potentially expanding utilization of Labcorp's diagnostic services across Epic-using institutions.

The expanded Epic collaboration builds on Labcorp's existing availability of Invitae genetic tests through the Aura platform. By making the full test menu available, Labcorp gains access to a significant portion of the U.S. hospital market, as Epic supports a substantial share of American health systems. The integration is designed to streamline operations for clinicians and care teams while improving access to diagnostic innovation as new tests are introduced.

Strategic Significance of the Epic Partnership

The expansion of Labcorp's integration with Epic's Aura platform represents a meaningful distribution and operational efficiency initiative. Epic Systems is the nation's leading electronic health record provider, supporting hospitals and health systems nationwide. By embedding Labcorp's full test menu directly into Epic workflows, the company reduces barriers to test ordering and results retrieval, potentially increasing test volume and market penetration. This type of integration is increasingly important in healthcare as providers seek to consolidate vendor relationships and streamline operational complexity.

Conclusion

Labcorp's expanded integration with Epic's Aura platform represents a strategic move to enhance distribution and operational efficiency within a major segment of the U.S. healthcare market. The collaboration allows Labcorp to embed its diagnostic services directly into the workflows of Epic-using hospitals and health systems, potentially reducing ordering friction and expanding test utilization. For U.S. investors, this partnership highlights Labcorp's focus on digital integration and market access expansion within the competitive diagnostic testing industry.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.